Navigation Links
Oramed Pharmaceuticals to Present at the 4th Annual Drug Delivery & Formulation Summit in Berlin
Date:2/18/2013

aching Phase 2a trials. The company's corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please visit  http://www.oramed.com.

The company's fact sheet, the content of which is not part of this press release, can be viewed here.

Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss our oral insulin and oral exenatide candidates approaching Phase 2 clinical trials under U.S. IND and 2a clinical trials, respectively. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attr
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Shares of Oramed Pharmaceuticals Are Approved for Listing on the Nasdaq Capital Market
2. Oramed Pharmaceuticals Inc. to Webcast, Live, at RetailInvestorConferences.com on February 7th
3. Oramed Pharmaceuticals Completes $5.6 Million Funding to Advance Clinical Trials
4. Oramed Pharmaceuticals to Present at the 12th Annual Diabetes Technology Society Meeting in Bethesda, MD, Nov 8-10, 2012
5. Oramed Pharmaceuticals Granted Core Technology Patent in New Zealand
6. Oramed Pharmaceuticals to Present at the 11th National Life Science & Technology Week ILSI-BIOMED Conference; Tel Aviv, Israel, 2012
7. Neurim Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of Piromelatine for the Treatment of Insomnia
8. Cumberland Pharmaceuticals To Announce 2012 Year End Financial Results On February 28, 2013
9. Coyote Pharmaceuticals Initiates GMP Manufacturing Process for CNS-102 Following Successful Pre-IND Meeting
10. Founder of Nestle-Acquired Company Joins Prismic Pharmaceuticals
11. RQx Pharmaceuticals and Genentech Enter Drug Discovery Collaboration to Develop Novel Drug Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... BOSTON , July 6, 2015 ... Inc. (NASDAQ: ISIS ), announced today that ... Orphan Drug Designation to volanesorsen (ISIS-APOCIII Rx ) ... Syndrome (FCS).  FCS is a rare genetic disease ... of pancreatitis. In a Phase 2 study published ...
(Date:7/5/2015)... 6, 2015 Nihon University is pleased ... on Medical-Engineering Collaboration "Medicine Definitely Jumps Up with ... in Tokyo, Japan . Many ... research will present their achievements and future prospects ... industry produced with 8K technology. (Documentation: ...
(Date:7/3/2015)... 4, 2015 Un fournisseur ... que sont l,hypertension, le diabète et les troubles ... l,intermédiaire de plateformes éducatives gratuites et d,une conférence ... (Photo: http://photos.prnewswire.com/prnh/20150630/227090 ) , ... en ligne , Prendre en charge l,hypertension ...
Breaking Medicine Technology:Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6Nihon University to Host International Symposium on Medical-Engineering Collaboration 2Nihon University to Host International Symposium on Medical-Engineering Collaboration 3Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 2Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 3
... 23, 2007 -,Gentium S.p.A. (NASDAQ: GENT) (the ... will be the subject of a poster,presentation ... being held in,Rio de Janeiro, Brazil from ... 2007, Cinara Echart, Ph.D., Manager of,Biological Research ...
... 24 /CNW/ - The weight loss medication Xenical,(orlistat ... such as blood pressure, glycaemic,control and lipid profile ... and hypertension, according to a study analysis,presented at ... ,This analysis strengthens the wealth of data already ...
Cached Medicine Technology:Gentium's Defibrotide Highlighted in Poster Presentation at World,Congress of Nephrology 2Gentium's Defibrotide Highlighted in Poster Presentation at World,Congress of Nephrology 3New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 2New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 3New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 4New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 5New Data Show Xenical Significantly Reduces Cardiovascular Risk and,More Than Doubles Weight Loss Achieved in Overweight and Obese,People 6
(Date:7/6/2015)... ... ... University of Pittsburgh Cancer Institute (UPCI) scientists recently led a ... available tests that better incorporate personalized medicine into diagnosing the condition. , Their ... published in the July issue of the scientific journal Thyroid . The ...
(Date:7/6/2015)... ... July 06, 2015 , ... Shortly after opening her ... the leading network of doctors working on a lien basis. Dr. Lim had ... , The daughter of two Cambodian refugees, Dr. Lim suffered with back pain herself ...
(Date:7/6/2015)... Virginia (PRWEB) , ... July 06, 2015 , ... ... choose fat-reduction procedures each year for aesthetic reasons, which is why liposuction regularly ... For a particular demographic, however, fat reduction has become more than a way ...
(Date:7/6/2015)... OH (PRWEB) , ... July 06, 2015 , ... ... the proper reimbursement for radiology services and ADVOCATE is leading the transition. ADVOCATE, ... their coding expertise with their Top 10 Tips for ICD-10. The ten tips ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... allows newly-diagnosed cancer patients, caregivers and medical professionals to chat with the CHN ... same cancer. , “Receiving a cancer diagnosis is often the most traumatic experience ...
Breaking Medicine News(10 mins):Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 2Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 3Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 4Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 5Health News:Respected Chiropractor Opens Office in Signal Hill/Cambodia Town and Joins Doctors on Liens 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 3Health News:ADVOCATE Takes the Lead to Ensure ICD-10 Success: “Top 10 Tips for ICD-10” 2Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2
... SALT LAKE CITY, Dec. 15 The new compact LifeSpan TR200 ... ), was highly praised by treadmill review groups in recent ... treadmill received awards for Best New Treadmill, Recommended Unique Design, and ... is designed for light use walking indoors in small workout spaces. ...
... study links chronic obstructive pulmonary disease, or COPD, with ... activate the body,s immune system. The University ... awareness of the immune system,s role in COPD, a ... million Americans with wheezing, shortness of breath, chest tightening ...
... increases risk in teens, study suggests , TUESDAY, Dec. ... obese increases the risk of obstructive sleep apnea, but ... younger children, Australian researchers have found. , In sleep ... 18, who were referred for evaluation of snoring and ...
... potential for injury when doctors decide benefits of imaging ... -- MRI scans can pose a serious risk to ... and Drug Administration researchers exposed pacemakers to a simulated ... produced at the tip of the pacemaker lead, where ...
... , ... Reportlinker.com announces that a new market research ... In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. ... , http://www.reportlinker.com/p0167482/In-Vitro-Diagnostic-Substance-Manufacturing-Industry-in-the-US-and-its-International-Trade-[Q4-2009-Edition].html , The newly published ...
... , , NEW YORK, ... new market research report is available in ... Cardiovascular Diseases Therapeutics - Market Forecasts to ... Analysis , http://www.reportlinker.com/p0168098/The-Future-of-Cardiovascular-Diseases-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html , ...
Cached Medicine News:Health News:Treadmill Reviews Rate Compact LifeSpan Treadmill Best Treadmill 2Health News:Immune cell activity linked to worsening COPD 2Health News:Immune cell activity linked to worsening COPD 3Health News:Puberty May Trigger Sleep Apnea in Overweight Kids 2Health News:Patients With Pacemakers Should Avoid MRI Scans 2Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 2Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 3Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 4Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 5Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 6Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 7Health News:Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 8Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 13Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 14Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 15Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 16Health News:Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 17
Inquire...
Superior imaging through a 410,000 pixel CCD, unseen color replication from a digital signal processor in the scope, and the added benefit of four way tip deflection make the TF410 a superior choice ...
The computer-optimized optical design produces large, brilliant images of high resolution....
ACMI™ Distortion-Free Laparoscopes utilize technical advances in optical lens design to provide images without the fish-eye effect typically found on the peripheral viewing edges of conventional...
Medicine Products: